Denintuzumab mafodotin

N/A

Report date: 2024/02/05 14:09:14

Base Information

Drug NameDenintuzumab mafodotin
Drug Alias NameSGN-19ASGN-CD19A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsB-lymphocyte antigen CD19 stimulants
TargetsB-lymphocyte antigen CD19Tubulin
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia